EF2 was over-expressed in colorectal and gastric cancers [102], and that was suggested to be due to EF2’s ability to stimulate the cell cycle progression at G2/M, cdc2, and Akt, resulting in cell growth enhancement [103]. Here, AKT1 is linked to gastric cancer.